| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Bjork Elisabeth is a Director at RCKT, with reported holdings spanning 2 companies. Recent filings cover 2 purchases and 2 sales. Those positions are worth an estimated $747K at current prices.
Bjork Elisabeth's largest disclosed position is in PHVS as Director, worth about $575K. The recent filings there lean toward selling, a net 62,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | PHVS Pharvaris N.V. | Director | Sale+OE | 52,500 | $37.89 | $1,989,408.75 | -77.6% | - | - | |
| May 20, 2026 | PHVS Pharvaris N.V. | Director | Sale+OE10b5-1 | 10,000 | $29.32 | $293,166.00 | -39.7% | +22.6% | - | |
| Jan 2, 2026 | RCKT Rocket Pharmaceuticals, Inc. | Director | Buy | 10,000 | $3.44 | $34,400.00 | +25.0% | +2.6% | - | |
| Aug 27, 2025 | RCKT Rocket Pharmaceuticals, Inc. | Director | Buy | 10,000 | $3.41 | $34,100.00 | +33.3% | -6.6% | +9.0% |